Roche Unveils New Data on Multiple Sclerosis Treatment
April 28 2020 - 02:25AM
Dow Jones News
By Olivia Bugault
Roche Holding AG said Tuesday that its Ocrevus treatment reduces
the risk of needing a walking aid in relapsing multiple sclerosis
patients by 49%, according to new data.
The analysis from six years of phase 3 open-label extension
studies shows that Ocrevus reduces the risk of disease and
disability progression for relapsing and primary progressive
multiple sclerosis, the Swiss pharmaceutical giant said.
Multiple sclerosis is a disease that occurs when the immune
system abnormally attacks the insulation and support around nerve
cells in the central nervous system, causing inflammation and other
damage, Roche said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
April 28, 2020 02:10 ET (06:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2023 to Mar 2024